Michael Rodriguez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6274117/publications.pdf

Version: 2024-02-01

24 papers 1,312 citations

16 h-index 642715 23 g-index

24 all docs

24 docs citations

times ranked

24

852 citing authors

#	Article	IF	CITATIONS
1	Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study. Gynecologic Oncology, 2015, 138, 101-108.	1.4	13
2	A Phase I Study of Oral Topotecan and Pegylated Liposomal Doxorubicin (Doxil) in Platinum-Resistant Ovarian and Peritoneal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 476-480.	1.3	16
3	Gemcitabine Reverses Cisplatin Resistance: Demonstration of Activity in Platinum- and Multidrug-Resistant Ovarian and Peritoneal Carcinoma. Gynecologic Oncology, 2003, 88, 17-21.	1.4	104
4	Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecologic Oncology, 2003, 89, 429-433.	1.4	77
5	Histologic Follow-up of Atypical Endocervical Cells. Acta Cytologica, 2002, 46, 453-457.	1.3	31
6	A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2002, 85, 136-139.	1.4	10
7	Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer. American Journal of Obstetrics and Gynecology, 2002, 187, 1728-1728.	1.3	11
8	Significance of Cytologically Normal Endometrial Cells in Cervical Smears from Postmenopausal Women. Acta Cytologica, 2001, 45, 153-156.	1.3	33
9	Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent Dosages. Gynecologic Oncology, 2001, 82, 323-328.	1.4	106
10	Improved Therapeutic Index of Lower Dose Topotecan Chemotherapy in Recurrent Ovarian Cancer. Gynecologic Oncology, 2001, 83, 257-262.	1.4	54
11	Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer. American Journal of Obstetrics and Gynecology, 2001, 185, 370-374.	1.3	101
12	A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma. Gynecologic Oncology, 2000, 78, 228-234.	1.4	39
13	Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2000, 18, 2957-2962.	1.6	22
14	Positron Emission Tomography for Evaluating Para-aortic Nodal Metastasis in Locally Advanced Cervical Cancer Before Surgical Staging: A Surgicopathologic Study. Journal of Clinical Oncology, 1999, 17, 41-41.	1.6	338
15	Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma. International Journal of Gynecological Cancer, 1999, 9, 448-451.	2.5	3
16	Atypical Squamous Cells of Undetermined Significance in Women Over 55. Acta Cytologica, 1999, 43, 357-362.	1.3	37
17	Peritoneal Washing Cytology of Ovarian Tumors of Low Malignant Potential. Acta Cytologica, 1998, 42, 1091-1094.	1.3	32
18	Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma Journal of Clinical Oncology, 1998, 16, 1494-1497.	1.6	125

#	Article	IF	CITATION
19	Malignant Mixed Mullerian Tumor of the Female Peritoneum: Treatment and Outcome of Three Cases. Gynecologic Oncology, 1997, 65, 523-525.	1.4	15
20	Conservative trends in the surgical management of vulvar cancer: a University of Miami patient care evaluation study. International Journal of Gynecological Cancer, 1997, 7, 151-157.	2.5	9
21	The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma: A preliminary report., 1996, 77, 2286-2293.		17
22	In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms. Anti-Cancer Drugs, 1995, 6, 94-100.	1.4	15
23	Paclitaxel: A Radiation Sensitizer of Human Cervical Cancer Cells. Gynecologic Oncology, 1995, 57, 165-169.	1.4	38
24	National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer, 1994, 73, 1245-1250.	4.1	66